F
François Desgrandchamps
Researcher at University of Paris
Publications - 209
Citations - 4396
François Desgrandchamps is an academic researcher from University of Paris. The author has contributed to research in topics: Bladder cancer & Transplantation. The author has an hindex of 31, co-authored 197 publications receiving 4004 citations. Previous affiliations of François Desgrandchamps include Paris Diderot University.
Papers
More filters
Journal ArticleDOI
Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival
Alexandre Loupy,Carmen Lefaucheur,Dewi Vernerey,Christof Prugger,Jean-Paul Duong Van Huyen,Nuala Mooney,Caroline Suberbielle,Véronique Frémeaux-Bacchi,Arnaud Mejean,François Desgrandchamps,Dany Anglicheau,Dominique Nochy,Dominique Charron,Jean-Philippe Empana,Michel Delahousse,Christophe Legendre,Denis Glotz,Gary S. Hill,Adriana Zeevi,Xavier Jouven +19 more
TL;DR: Assessment of the complement-binding capacity of donor-specific anti-HLA antibodies appears to be useful in identifying patients at high risk for kidney-allograft loss.
Journal ArticleDOI
EAU Guidelines on Benign Prostatic Hyperplasia (BPH)
Jean J.M.C.H. de la Rosette,Gerasimos Alivizatos,S. Madersbacher,M. Perachino,David F.M. Thomas,François Desgrandchamps,Michel J.A.M. de Wildt +6 more
TL;DR: Recommendations for assessment, possible therapeutic options, and follow–up of patients with BPH are made and the International Prostate Symptom Score is recommended.
Journal ArticleDOI
High-intensity focused ultrasound and localized prostate cancer: Efficacy results from the European multicentric study
Stefan Thüroff,Christian Chaussy,Guy Vallancien,Wolfgang Wieland,Halas J. Kiel,Alain Le Duc,François Desgrandchamps,Jean J.M.C.H. de la Rosette,Albert Gelet +8 more
TL;DR: These short-term results obtained on a large cohort confirm that HIFU is an option to be considered for the primary treatment of localized prostate cancer.
Journal ArticleDOI
A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G
TL;DR: A systematic review shows that antibodies blocking immune checkpoints offer interesting and long-lasting response rates in heavily pretreated patients with advanced urologic cancers, alone or in combination with conventional cancer therapies.
Journal Article
Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface.
R. Lubin,Beata Schlichtholz,Bengoufa D,Gérard Zalcman,Jean Trédaniel,A. Hirsch,C.Caron de Fromentel,Claude Preudhomme,Pierre Fenaux,Georges Fournier,Philippe Mangin,Pierre Laurent-Puig,Gilles Pelletier,M. Schlumberger,François Desgrandchamps,A. Le Duc,Jean-Philippe Peyrat,Nicolas Janin,B. Bressac,Thierry Soussi +19 more
TL;DR: It is proposed that the p53 humoral response is the result of a self-immunization process which is itself the consequence of p53 protein accumulation in tumor cells.